Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery.
Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.
Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.
Marie
M
Stark
Department of Molecular and Cellular Biology, University of California, Davis, CA, USA.
R Holland
RH
Cheng
D000818:Animals; D036022:Capsid Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics; D018014:Gene Transfer Techniques / Q000639:trends; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D016752:Hepatitis E virus / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009369:Neoplasms / Q000235:genetics / Q000628:therapy
D036022:Capsid Proteins
cancer targeting; nanotheranostics; viral capsid